Your session is about to expire
← Back to Search
Technology-Enhanced Family Navigation for Autism (ATTAIN NAV Trial)
N/A
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up distributed at study completion, an average of 1 year.
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to help families of children with autism and additional mental health issues by using specially trained guides called Family Navigators. These guides will use new technology tools to make it easier for families to find and use mental health services. The goal is to ensure that children get the right help quickly and effectively.
Who is the study for?
This trial is for children aged 4-16 with autism, who speak English or Spanish and are getting care at a participating practice. Caregivers of these children can also participate. Healthcare providers must work at the practice and have experience with autistic kids. For part of the study, kids need an official autism diagnosis and show significant symptoms on a checklist.
What is being tested?
The ATTAIN NAV model is being tested to see if it helps families get mental health services faster for their autistic children in primary care settings. It's about adapting family navigation using technology to improve access to care.
What are the potential side effects?
Since this intervention involves technology-enhanced services rather than medication, there aren't typical medical side effects; however, participants may experience increased stress or frustration if they encounter difficulties navigating the system.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ distributed at study completion, an average of 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~distributed at study completion, an average of 1 year.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Acceptability of Intervention Measure (AIM)
Appropriateness of Intervention Measure (AIM)
Eyberg Child Behavior Inventory (ECBI)
+5 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Stage 3 EnrollmentExperimental Treatment1 Intervention
Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
Group II: Stage 2 EnrollmentExperimental Treatment1 Intervention
Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
Group III: Stage 1 EnrollmentExperimental Treatment1 Intervention
Enrollment of 2 clinics over 4 months including 5 PCPs per clinic (2 total clinics).
Group IV: 1 Month Baseline PeriodActive Control1 Intervention
Initial baseline period for rollout at 6 different clinics throughout the year-long intervention period using a step-wedge design.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Autism Spectrum Disorder (ASD) include behavioral and educational interventions such as Applied Behavior Analysis (ABA), the Early Start Denver Model (ESDM), and the SCERTS program. These interventions work by improving social communication, adaptive behaviors, and cognitive functions through structured, individualized programs.
Family involvement is crucial, as parent-mediated interventions enhance the effectiveness of these treatments by promoting consistent, supportive interactions at home. This comprehensive approach helps ASD patients by addressing core symptoms, improving daily functioning, and fostering independence, which is essential for their long-term development and quality of life.
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials.Basic science and treatment innovation.
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials.Basic science and treatment innovation.
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,187 Previous Clinical Trials
1,576,657 Total Patients Enrolled
9 Trials studying Autism Spectrum Disorder
14,755 Patients Enrolled for Autism Spectrum Disorder
Kaiser PermanenteOTHER
554 Previous Clinical Trials
27,731,564 Total Patients Enrolled
3 Trials studying Autism Spectrum Disorder
361 Patients Enrolled for Autism Spectrum Disorder
National Institute of Mental Health (NIMH)NIH
2,928 Previous Clinical Trials
2,744,795 Total Patients Enrolled
84 Trials studying Autism Spectrum Disorder
41,062 Patients Enrolled for Autism Spectrum Disorder
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: 1 Month Baseline Period
- Group 2: Stage 1 Enrollment
- Group 3: Stage 2 Enrollment
- Group 4: Stage 3 Enrollment
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.